At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 671 enrolled
Drug / intervention
Bevacizumab as MYL-1402O +1 morebiological
Likely dose
Bevacizumab as MYL-1402O 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Bevacizumab as MYL-1402O and Bevacizumab as Avastin for NSCLC Stage IV. Completed, enrolled 671 participants across 102 sites in 17 countries.
Detailed Summary
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC Stage IV
CountriesBelarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Hungary, India, Italy, Philippines, Poland, Romania, Russia, Spain, Taiwan, Turkey (Türkiye), Ukraine, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
Primary CompletionJun 2019
Study CompletionNov 2019
First PostedNov 2020
TodayJul 2026
First PostedNov 18, 2020
Enrollment StartJan 21, 2017
Primary CompletionJun 5, 2019
Study CompletionNov 22, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.6 years ago
Interventions
Bevacizumab as MYL-1402Obiological
Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
Bevacizumab as Avastinbiological
Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV